Omega-3 EPA/DHA: the dose that actually works

If you've been taking a fish oil softgel every morning and wondering whether it's actually doing anything, the honest answer is: probably not much, at that dose. The gap between what most consumer omega-3 products deliver and what the clinical trials used is wide — and it's the reason so many people take fish oil for years without seeing their inflammation labs budge.

This is a dosing problem, not an omega-3 problem.

What EPA and DHA actually do in plain English

EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) are the two long-chain omega-3 fatty acids your body uses to build anti-inflammatory signaling molecules called resolvins and protectins. They compete with omega-6 arachidonic acid for the same enzymatic machinery, so raising EPA/DHA tissue levels shifts the downstream signaling toward resolution of inflammation rather than propagation.

That's the mechanism. The clinical translation shows up in a few specific places:

• hs-CRP (high-sensitivity C-reactive protein), a systemic inflammation marker
• Triglycerides, which drop meaningfully at pharmacologic doses
• Omega-3 Index, the percentage of EPA+DHA in your red blood cell membranes
• Resting heart rate and blood pressure, modestly

ALA (the plant omega-3 in flax and chia) converts to EPA at roughly 5–10% and to DHA at under 1% in most adults. That's why the dosing conversation is specifically about EPA and DHA from marine sources — not "omega-3s" generically.

Why 1,000 mg of fish oil is almost certainly not enough

Here's where labels get confusing. A softgel marketed as "1,000 mg fish oil" typically contains around 300 mg of combined EPA and DHA. The other 700 mg is other fatty acids and the triglyceride or ethyl ester backbone.

So if the label says one softgel is 1,000 mg and you take one a day, your actual EPA+DHA dose is closer to 300 mg. That's roughly a tenth of what the inflammation trials used.

The major cardiovascular and inflammation trials — REDUCE-IT, JELIS, and the dose-response work summarized by Skulas-Ray and colleagues in a 2019 AHA Science Advisory — landed on 2 to 4 grams per day of combined EPA/DHA for meaningful triglyceride reduction (typically 20–30%) and measurable hs-CRP changes. General cardiovascular maintenance doses in the guidelines sit lower, around 1 gram per day of EPA+DHA, but that's a maintenance number, not an anti-inflammatory number.

If the label doesn't clearly state the milligrams of EPA and DHA separately, assume you're taking less than you think.

The dose that actually moves the needle

For an adult targeting inflammation markers or elevated triglycerides, the evidence-based range looks like this:

• General cardiovascular support: 1,000 mg/day combined EPA + DHA
• Elevated triglycerides or elevated hs-CRP: 2,000–4,000 mg/day combined EPA + DHA
• Prescription-grade indication (severe hypertriglyceridemia ≥500 mg/dL): 4,000 mg/day, physician-directed

The higher end (4 g/day) is where the REDUCE-IT trial saw a 25% relative risk reduction in major cardiovascular events, though that trial used icosapent ethyl — a purified EPA-only prescription product — which complicates direct translation to over-the-counter fish oil.

Split the dose. Two or three servings with meals containing fat improves absorption meaningfully compared to a single fasted dose, and reduces the fishy reflux most people complain about.

The number that mattersRead the back of the label for "EPA" and "DHA" in milligrams — not the front-of-bottle "fish oil" number. If those two numbers don't add up to at least 1,000 mg per serving, you'll be swallowing a lot of softgels to hit an anti-inflammatory dose.

EPA vs. DHA: does the ratio matter?

Somewhat. EPA appears to do more of the heavy lifting on triglycerides and cardiovascular endpoints, which is why prescription icosapent ethyl is pure EPA. DHA is preferentially incorporated into brain and retinal tissue and appears more relevant for neurological and cognitive endpoints.

For most adults chasing inflammation and lipid goals, a product with more EPA than DHA (roughly a 2:1 or 3:2 ratio) is reasonable. For cognitive or pregnancy-related goals, DHA-forward products make more sense. Both molecules are useful; the ratio is a fine-tuning question, not a make-or-break one.

How to verify it's working: the labs worth checking

This is where dosing becomes evidence-based instead of hopeful. The single most useful test is the Omega-3 Index, a red blood cell membrane assay that reports EPA+DHA as a percentage of total fatty acids.

• Below 4%: high cardiovascular risk zone
• 4–8%: intermediate
• Above 8%: target zone associated with the lowest event rates in observational data

Most untreated Americans sit between 4% and 5%. Reaching 8%+ typically requires 2 grams per day or more of EPA/DHA sustained for 3–4 months, because red cell turnover takes about 120 days.

The other markers worth watching alongside a serious omega-3 protocol:

• hs-CRP — expect modest reductions if starting elevated
• Triglycerides — the most reliably responsive marker
• Fasting lipid panel — LDL can nudge upward slightly at high doses, worth knowing
• ALT/AST — baseline liver enzymes, since omega-3s are processed hepatically

A thorough workup for someone starting a therapeutic-dose omega-3 protocol would typically include those markers at baseline and again at 12–16 weeks.

Quality issues nobody talks about

Oxidation. Omega-3s are polyunsaturated and chemically fragile, and a meaningful percentage of retail fish oil is rancid by the time you swallow it. Rancid fish oil is not just useless — it delivers oxidized lipid byproducts you'd rather not have.

Signs and safeguards:

• Bite a softgel. It should taste clean and mildly marine, not sharply fishy or metallic.
• Look for a third-party purity certification (IFOS, USP, or NSF).
• Check the peroxide value and TOTOX on the certificate of analysis if the brand publishes one.
• Store in the fridge once opened.
• Prefer triglyceride-form or re-esterified triglyceride products over ethyl ester when possible; absorption is modestly better.

Who should be cautious with high-dose omega-3s

Few people run into trouble, but the situations that warrant a clinician conversation before pushing to 3–4 g/day:

• Anyone on anticoagulants (warfarin, apixaban, rivaroxaban) — omega-3s have mild antiplatelet effects
• Scheduled surgery within the next two weeks
• History of atrial fibrillation — some high-dose trials showed a small AF signal
• Active fish or shellfish allergy (algae-based DHA/EPA is a workable alternative)

These aren't disqualifiers. They're reasons to make the dose decision with someone who knows your full context.

The takeaway

Omega-3s are one of the better-studied supplements in existence, and they work — at the right dose. The right dose for moving inflammation markers is 2 to 4 grams per day of combined EPA and DHA, split across meals, from a third-party-tested product, sustained for at least three months before you re-test.

A single 1,000 mg softgel of generic fish oil isn't going to change your labs. Reading the actual EPA and DHA numbers on the back of the bottle is the first step; verifying with an Omega-3 Index or a repeat lipid panel is the second.

References

1. Omega-3 Fatty Acids: Fact Sheet for Health Professionals. NIH Office of Dietary Supplements. Source

Editorial disclosure: This article is for informational purposes only and does not constitute medical advice. All treatments at DirectCare AI are prescribed by US-licensed clinicians based on individual medical evaluation. Compounded medications are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality. Always consult a US-licensed clinician before starting or changing any therapy.